Skip to main content

Table 3 Univariate and multivariate analysis of overall survival (training cohort, n = 248)

From: AGLR is a novel index for the prognosis of hepatocellular carcinoma patients: a retrospective study

Clinical character Univariate analysis Multivariate analysis
HR (95% CI) p value HR (95% CI) p value
AGLR level (> 90 vs ≤ 90) 2.66 (2.01–3.88)  < 0.001 1.79 (1.21–2.69)  < 0.001
Age, years (> 60 vs ≤ 60) 1.24 (0.81–1.83) 0.308   
Gender (male vs female) 1.23 (0.72–1.91) 0.441   
Drinking (yes vs no) 1.03 (0.74–1.41) 0.862   
HBsAg (positive vs negative) 1.29 (0.78–2.06) 0.303   
AFP, ng/ml (> 20 vs ≤ 20) 1.71 (1.19–2.47) 0.003 1.13 (0.77–1.67) 0.514
Liver cirrhosis (yes vs no) 1.03 (0.51–2.09) 0.930   
Tumor size, cm (> 5 vs ≤ 5) 2.86 (1.97–3.91)  < 0.001 1.91 (1.27–2.61)  < 0.001
Tumor number (multiple vs single) 1.60 (1.13–2.26) 0.006 1.12 (0.81–1.53) 0.460
TNM stage (III–IV vs I–II) 1.96 (1.39–2.77)  < 0.001 1.52 (1.03–2.31) 0.025
MVI (yes vs no) 2.57 (1.93–3.74)  < 0.001 1.61 (1.23–2.39) 0.007
Recurrence (yes vs no) 2.70 (1.69–3.59)  < 0.001 2.01 (1.47–2.83)  < 0.001
  1. CI, confidence interval; HR, hazard ratio; AGLR, alkaline phosphatase plus gamma-glutamyl transpeptidase to lymphocyte ratio; HBsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis; MVI, microvascular invasion